Benefits and Limits of Antiretroviral Drug Monitoring in Routine Practice

Author(s): Thomas Maitre*, Patrice Muret, Mathieu Blot, Anne Waldner, Michel Duong, Ali SI-Mohammed, Pascal Chavanet, Serge Aho, Lionel Piroth.

Journal Name: Current HIV Research

Volume 17 , Issue 3 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: HIV infection is a chronic disease for which therapeutic adherence and tolerance require particular attention.

Objective: This study aimed to assess whether and when therapeutic drug monitoring (TDM) could be associated with a benefit in routine practice.

Methods: All HIV-infected patients who underwent at least one TDM at the University Hospital of Dijon (France) between 1st January 2009 and 31st December 2012 were retrospectively included. Compliance with the recommendations, the results (antiretroviral concentrations), any subsequent therapeutic modifications, and the virological results at 4-8 months were analysed each time TDM was performed. TDM was defined as “practically relevant” when low or high antiretroviral concentrations led to a change in therapy.

Results: Of the 571 patients who followed-up, 43.4% underwent TDM. TDM complying with recommendations (120 patients) was associated with a higher proportion of antiretroviral concentrations outside the therapeutic range (p=0.03). Antiretroviral treatment was modified after TDM in 22.6% of patients. Protease inhibitors, non-nucleoside reverse transcriptase inhibitors and raltegravir were more significantly modified when the measured concentration was outside the therapeutic range (p=0.008, p=0.05 and p=0.02, respectively). Overall, 11.7% of TDM was considered “practically relevant”, though there was no significant correlation between subsequent changes in antiretroviral treatment and undetectable final HIV viral load.

Conclusion: TDM may be a useful tool in the management of HIV infection in specific situations, but the overall benefit seems moderate in routine practice. TDM cannot be systematic and/or a decision tool per se, but should be included in a comprehensive approach in certain clinical situations.

Keywords: Therapeutic drug monitoring, routine, benefit, antiretroviral, HIV, guidelines.

[1]
Palella FJ Jr, Delaney KM, Moorman AC, et al. HIV Outpatient Study Investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338(13): 853-60.
[http://dx.doi.org/10.1056/NEJM199803263381301] [PMID: 9516219]
[2]
Siddiqi AE, Hu X, Hall HI. Centers for Disease Control and Prevention (CDC). Mortality among blacks or African Americans with HIV infection-United States, 2008-2012. MMWR Morb Mortal Wkly Rep 2015; 64(4): 81-6.
[PMID: 25654607]
[3]
Marston M, Michael D, Wringe A, et al. The impact of antiretroviral therapy on adult mortality in rural Tanzania. Trop Med Int Health 2012; 17(8): e58-65.
[http://dx.doi.org/10.1111/j.1365-3156.2011.02924.x] [PMID: 22943380]
[4]
Casper C, Crane H, Menon M, Money D. HIV/AIDS Comorbidities: Impact on Cancer, Noncommunicable Diseases, and Reproductive Health. Holmes KK, Bertozzi S, Bloom BR, Jha P, éditeurs. In: Major Infectious Diseases [Internet]. 3rd éd.. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017.[Accessed on 17 July 2019]. Available from: sur.. http://www.ncbi.nlm.nih.gov/books/NBK525185/
[5]
Ramlagan S, Rodriguez VJ, Peltzer K, Ruiter RAC, Jones DL, Sifunda S. Self-Reported Long-Term Antiretroviral Adherence: A Longitudinal Study Among HIV Infected Pregnant Women in Mpumalanga, South Africa. AIDS Behav 2019; 21.
[http://dx.doi.org/10.1007/s10461-019-02563-z] [PMID: 31228026]
[6]
Neupane S, Dhungana GP, Ghimire HC. Adherence to antiretroviral treatment and associated factors among people living with HIV and AIDS in CHITWAN, Nepal. BMC Public Health 2019; 19(1): 720.
[http://dx.doi.org/10.1186/s12889-019-7051-3] [PMID: 31182074]
[7]
Dachew BA, Tesfahunegn TB, Birhanu AM. Adherence to highly active antiretroviral therapy and associated factors among children at the University of Gondar Hospital and Gondar Poly Clinic, Northwest Ethiopia: a cross-sectional institutional based study. BMC Public Health 2014; 14: 875.
[http://dx.doi.org/10.1186/1471-2458-14-875] [PMID: 25155293]
[8]
Bertrand L, Velichkovska M, Toborek M. Cerebral Vascular Toxicity of Antiretroviral Therapy. J Neuroimmune Pharmacol 2019. [E-pub Ahead of Print]
[9]
Chawla A, Wang C, Patton C, et al. A Review of Long-Term Toxicity of Antiretroviral Treatment Regimens and Implications for an Aging Population. Infect Dis Ther 2018; 7(2): 183-95.
[http://dx.doi.org/10.1007/s40121-018-0201-6] [PMID: 29761330]
[10]
Kanters S, Vitoria M, Doherty M, et al. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis. Lancet HIV 2016; 3(11): e510-20.
[http://dx.doi.org/10.1016/S2352-3018(16)30091-1] [PMID: 27658869]
[11]
Sadashiv MS, Rupali P, Manesh A, et al. Risk factors of clinical and immunological failure in south indian cohort on generic antiretroviral therapy. J Assoc Physicians India 2017; 65(12): 34-9.
[PMID: 29327520]
[12]
Bezabhe WM, Chalmers L, Bereznicki LR, Peterson GM. Adherence to antiretroviral therapy and virologic failure: A meta-analysis. Medicine (Baltimore) 2016; 95(15)e3361
[http://dx.doi.org/10.1097/MD.0000000000003361] [PMID: 27082595]
[13]
Acosta EP, Gerber JG. Adult pharmacology committee of the AIDS clinical trials group. Position paper on therapeutic drug monitoring of antiretroviral agents. AIDS Res Hum Retroviruses 2002; 18(12): 825-34.
[http://dx.doi.org/10.1089/08892220260190290] [PMID: 12201904]
[14]
Fernandez-Montero JV, Eugenia E, Barreiro P, Labarga P, Soriano V. Antiretroviral drug-related toxicities - clinical spectrum, prevention, and management. Expert Opin Drug Saf 2013; 12(5): 697-707.
[http://dx.doi.org/10.1517/14740338.2013.806480] [PMID: 23730950]
[15]
Kang JS, Lee MH. Overview of therapeutic drug monitoring. Korean J Intern Med (Korean Assoc Intern Med) 2009; 24(1): 1-10.
[http://dx.doi.org/10.3904/kjim.2009.24.1.1] [PMID: 19270474]
[16]
Nettles RE, Kieffer TL, Parsons T, et al. Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clin Infect Dis 2006; 42(8): 1189-96.
[http://dx.doi.org/10.1086/501458] [PMID: 16575741]
[17]
Fletcher CV, Anderson PL, Kakuda TN, et al. Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. AIDS 2002; 16(4): 551-60.
[http://dx.doi.org/10.1097/00002030-200203080-00006] [PMID: 11872998]
[18]
Churchill D, Waters L, Ahmed N, et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015. HIV Med 2016; 17(Suppl. 4): s2-s104.
[http://dx.doi.org/10.1111/hiv.12426] [PMID: 27568911]
[19]
Morlat P. Prise en charge des personnes vivant avec le VIH, recommandations du groupe d’expert 2013.
[20]
Punyawudho B, Singkham N, Thammajaruk N, et al. Therapeutic drug monitoring of antiretroviral drugs in HIV-infected patients. Expert Rev Clin Pharmacol 2016; 9(12): 1583-95.
[http://dx.doi.org/10.1080/17512433.2016.1235972] [PMID: 27626677]
[21]
van Luin M, Kuks PF, Burger DM. Use of therapeutic drug monitoring in HIV disease. Curr Opin HIV AIDS 2008; 3(3): 266-71.
[http://dx.doi.org/10.1097/COH.0b013e3282f82c1b] [PMID: 19372977]
[22]
Bazzoli C, Jullien V, Le Tiec C, Rey E, Mentré F, Taburet A-M. Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action. Clin Pharmacokinet 2010; 49(1): 17-45.
[http://dx.doi.org/10.2165/11318110-000000000-00000] [PMID: 20000887]
[23]
Boffito M, Jackson A, Amara A, et al. Pharmacokinetics of once-daily darunavir-ritonavir and atazanavir-ritonavir over 72 hours following drug cessation. Antimicrob Agents Chemother 2011; 55(9): 4218-23.
[http://dx.doi.org/10.1128/AAC.01747-10] [PMID: 21709075]
[24]
Liu X, Ma Q, Zhang F. Therapeutic drug monitoring in highly active antiretroviral therapy. Expert Opin Drug Saf 2010; 9(5): 743-58.
[http://dx.doi.org/10.1517/14740331003767395] [PMID: 20350281]
[25]
Usach I, Melis V, Peris J-E. Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability. J Int AIDS Soc 2013; 16: 1-14.
[http://dx.doi.org/10.7448/IAS.16.1.18567] [PMID: 24008177]
[26]
Zeldin RK, Petruschke RA. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother 2004; 53(1): 4-9.
[http://dx.doi.org/10.1093/jac/dkh029] [PMID: 14657084]
[27]
Acosta EP, Kakuda TN, Brundage RC, Anderson PL, Fletcher CV. Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors. Clin Infect Dis 2000; 30(Suppl. 2): S151-9.
[http://dx.doi.org/10.1086/313852] [PMID: 10860900]
[28]
Chandwani A, Shuter J. Lopinavir/ritonavir in the treatment of HIV-1 infection: a review. Ther Clin Risk Manag 2008; 4(5): 1023-33.
[PMID: 19209283]
[29]
Edward P, Acosta J, Daniel R. Antiretroviral pharmacokinetics, resistance testing, and therapeutic drug monitoring in HIV. United States: American College of Physicians 2007; pp. 115-36.
[30]
Fayet Mello A, Buclin T, Decosterd LA, et al. Successful efavirenz dose reduction guided by therapeutic drug monitoring. Antivir Ther (Lond) 2011; 16(2): 189-97.
[http://dx.doi.org/10.3851/IMP1742] [PMID: 21447868]
[31]
Solas C, Gagnieu M-C. roupe Suivi Therapeutique Pharmacologique de la Societe Francaise de Pharmacologie et de Therapeutique.. [Evidence-based therapeutic drug monitoring for efavirenz]. Therapie 2011; 66(3): 197-205.
[http://dx.doi.org/10.2515/therapie/2011033] [PMID: 21819803]
[32]
Muret P, Piedoux S, Solas C, Quaranta S. Groupe Suivi Therapeutique Pharmacologique de la Societe Francaise de Pharmacologie et de Therapeutique.. [Evidence-based therapeutic drug monitoring for nevirapine] Therapie 2011; 66(3): 187-95.
[http://dx.doi.org/10.2515/therapie/2011030] [PMID: 21819802]
[33]
Mulubwa M, Rheeders M, Fourie C, Viljoen M. Associations between plasma tenofovir concentration and renal function markers in HIV-infected women. South Afr J HIV Med 2016; 17(1): 458.
[http://dx.doi.org/10.4102/sajhivmed.v17i1.458] [PMID: 29568614]
[34]
Kunimoto Y, Ikeda H, Fujii S, et al. Plasma tenofovir trough concentrations are associated with renal dysfunction in Japanese patients with HIV infection: a retrospective cohort study. J Pharm Health Care Sci 2016; 2: 22.
[http://dx.doi.org/10.1186/s40780-016-0056-5] [PMID: 27688900]
[35]
Holt SG, Gracey DM, Levy MT, et al. A consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection. AIDS Res Ther 2014; 11: 35.
[http://dx.doi.org/10.1186/1742-6405-11-35] [PMID: 25745499]
[36]
Jafari A, Khalili H, Dashti-Khavidaki S. Tenofovir-induced nephrotoxicity: incidence, mechanism, risk factors, prognosis and proposed agents for prevention. Eur J Clin Pharmacol 2014; 70(9): 1029-40.
[http://dx.doi.org/10.1007/s00228-014-1712-z] [PMID: 24958564]
[37]
Schoenenberger JA, Aragones AM, Cano SM, et al. The advantages of therapeutic drug monitoring in patients receiving antiretroviral treatment and experiencing medication-related problems. Ther Drug Monit 2013; 35(1): 71-7.
[http://dx.doi.org/10.1097/FTD.0b013e3182791f8c] [PMID: 23188184]
[38]
Bossi P, Peytavin G, Ait-Mohand H, et al. GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy. HIV Med 2004; 5(5): 352-9.
[http://dx.doi.org/10.1111/j.1468-1293.2004.00234.x] [PMID: 15369510]
[39]
Fabbiani M, Bracciale L, Ragazzoni E, et al. Relationship between antiretroviral plasma concentration and emergence of HIV-1 resistance mutations at treatment failure. Infection 2011; 39(6): 563-9.
[http://dx.doi.org/10.1007/s15010-011-0183-8] [PMID: 21866336]
[40]
Rendón A, Núñez M, Jiménez-Nácher I, González de Requena D, González-Lahoz J, Soriano V. Clinical benefit of interventions driven by therapeutic drug monitoring. HIV Med 2005; 6(5): 360-5.
[http://dx.doi.org/10.1111/j.1468-1293.2005.00321.x] [PMID: 16156885]
[41]
Johnston V, Cohen K, Wiesner L, et al. Viral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch. J Infect Dis 2014; 209(5): 711-20.
[http://dx.doi.org/10.1093/infdis/jit411] [PMID: 23943851]
[42]
Ahoua L, Guenther G, Pinoges L, et al. Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda. BMC Infect Dis 2009; 9: 81.
[http://dx.doi.org/10.1186/1471-2334-9-81] [PMID: 19493344]
[43]
de Maat MMR, Huitema ADR, Mulder JW, et al. Subtherapeutic antiretroviral plasma concentrations in routine clinical outpatient HIV care. Ther Drug Monit 2003; 25(3): 367-73.
[http://dx.doi.org/10.1097/00007691-200306000-00018] [PMID: 12766566]
[44]
Whitfield T, Dessain A, Taylor K, et al. The use of TDM in pregnant HIV-positive women: a retrospective cross-sectional review of five years practice in two large hospitals in Manchester. J Int AIDS Soc 2014; 17(4)(Suppl. 3): 19695.
[http://dx.doi.org/10.7448/IAS.17.4.19695] [PMID: 25397445]
[45]
Buckoreelall K, Cressey TR, King JR. Pharmacokinetic optimization of antiretroviral therapy in pregnancy. Clin Pharmacokinet 2012; 51(10): 639-59.
[http://dx.doi.org/10.1007/s40262-012-0002-0] [PMID: 23018528]
[46]
Lopez-Cortes LF, Ruiz-Valderas R, Rivero A, et al. Efficacy of low-dose boosted saquinavir once daily plus nucleoside reverse transcriptase inhibitors in pregnant HIV-1-infected women with a therapeutic drug monitoring strategy. Ther Drug Monit 2007; 29(2): 171-6.
[http://dx.doi.org/10.1097/FTD.0b013e31803bb54e] [PMID: 17417070]
[47]
Mirochnick M, Best BM, Stek AM, et al. Atazanavir pharmacokinetics with and without tenofovir during pregnancy J Acquir Immune Defic Syndr 1999 2011; 15(5): 412-9.
[48]
Philippe Morlat CNS. CNS, ANRS Prise en charge médicale des personnes vivants avec le VIH La documentation Française.. 2013..
[49]
Burger D, Hugen P, Reiss P, et al. ATHENA Cohort Study Group. Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. AIDS 2003; 17(8): 1157-65.
[http://dx.doi.org/10.1097/00002030-200305230-00007] [PMID: 12819517]
[50]
Best BM, Goicoechea M, Witt MD, Miller L, Daar ES, Diamond C, et al. A randomized controlled trial of therapeutic drug monitoring in treatment-naive and experienced HIV-1-infected patients. J Acquir Immune Defic Syndr 1999 1 déc 2007; 46(4): 433-2.
[51]
Demeter LM, Jiang H, Mukherjee AL, et al. A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced, HIV-1-infected patients. AIDS 2009; 23(3): 357-68.
[http://dx.doi.org/10.1097/QAD.0b013e32831f9148] [PMID: 19114860]
[52]
Khoo SH, Lloyd J, Dalton M, et al. Pharmacologic optimization of protease inhibitors and nonnucleoside reverse transcriptase inhibitors (POPIN)--a randomized controlled trial of therapeutic drug monitoring and adherence support. J Acquir Immune Defic Syndr 1999 1 2006; 41(4): 461-7.
[53]
Albrecht M, Mukherjee AL, Tierney C, et al. A randomized clinical trial evaluating therapeutic drug monitoring (TDM) for protease inhibitor-based regimens in antiretroviral-experienced HIV-infected individuals: week 48 results of the A5146 study. HIV Clin Trials 2011; 12(4): 201-14.
[http://dx.doi.org/10.1310/hct1204-201] [PMID: 22044856]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 17
ISSUE: 3
Year: 2019
Page: [190 - 197]
Pages: 8
DOI: 10.2174/1570162X17666190903232053
Price: $65

Article Metrics

PDF: 24
HTML: 4
EPUB: 1
PRC: 1